We're passionate about the early detection of TBI
BrainScope Company, Inc. is a medical neuro-technology company that is pioneering the future of traumatic brain injury (TBI) assessment. The company’s innovative BrainScope One system (FDA cleared as Ahead 300) is an easy-to-use, non-invasive, hand-held platform that empowers physicians to make more accurate TBI assessments quickly and at the point-of-care. BrainScope’s unique system leverages advanced digital signal processing, sophisticated algorithms and machine learning technologies to identify and evaluate key brain electrical activity biomarkers of TBI. BrainScope One also includes digitized versions of standard clinical assessments for milder forms of TBI known as concussion.
Results from clinical studies utilizing BrainScope’s technology have been independently published through 23 articles in leading peer-reviewed neurotrauma and emergency medicine journals.
BrainScope has been awarded more than $27 million of U.S. Department of Defense research contracts for the development of its TBI and concussion assessment technology and has received two awards from GE and the NFL through its Head Health Challenge I. The company has received significant funding from private investors including Revolution (created by AOL co-founder Steve Case), State of Maryland Venture Fund, ZG Ventures, Brain Trust Accelerator Fund, Difference Capital and DBL Partners.